615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Innovative induction regimens in AML: data from real life and clinical trials

31 ASH denotes this abstract as clinically relevant 

Juliette Lambert, Jérôme Lambert, Emilie Lemasle, et al.

Elderly patients with de novo AML at standard risk are unable to benefit from GO first-line instead of idarubicin in combination with cytarabine. With the reduced dosage regimen, GO had significant toxicities in this study. The incidence of recurrence was non-significant higher, and there was a shorter EFS and a shorter OS.


32 ASH denotes this abstract as clinically relevant 

Justin Grenet, Akriti G Jain, Madelyn Burkart, et al.

The study showed a significant difference in the overall survival (OS) in favor of CPX-351. This was observed both in the overall cohort and in several clinical subgroups. On the other hand, no difference was found in CR + CRi and RFS. The survival benefit in the CPX-351 group is due to higher HSCT rates in patients treated with CPX-351. Without HSCT, there was no difference in CR + CRi, RFS and OS between the treatment groups. Higher HSCT rates in the CPX-351 cohort are probably due to fewer comorbidities in CPX-351-treated patients. Other biases are also possible. Comorbidity analyzes are still pending.


33 ASH denotes this abstract as clinically relevant 

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.

CPX-351 is an efficient treatment for high-risk AML patients. This therapy allows Allo-HCT in many patients and gives encouraging outcome results after the transplantation.



Colin D. Godwin, Megan Othus, Mary-Elizabeth M. Percival, et al.

In adults with newly diagnosed AML / HG-MN, CLAG-M with fractionated dose GO leads to an MRD-negative CR / CRi rate of 75 percent. The 6-month EFS rate is 73 percent.



Suning Chen, Jundan Xie, Xiaofei Yang, et al.

Venetoclax plus decitabine is an effective, lower-intensity regimen. It is well tolerated by young adults with newly diagnosed ELN adverse-risk AML. It leads to high CR rates, low infection and early death rates.



Mithun V. Shah, Rakchha Chhetri, Ruchita Dholakia, et al.

In a subset of patients, VEN resulted in remission, including MRD(-) remission. With continued VEN therapy, 83 percent progressed. PFS and OS were short overall. Neither the morphological diagnosis of t-MDS / t-AML nor the proportion of blasts at the start of VEN therapy could influence the result. An earlier start of therapy with VEN gave better results. Using HMA-based therapies and achieving a deeper response also resulted in better outcomes.